Results 161 to 170 of about 2,518,442 (298)

The expression profile and clinical relevance of miR-125a-5p in individuals with chronic periodontitis. [PDF]

Acta Odontol Scand
Li S, Fang B, Sun Q.
europepmc   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Cytokine expression profile in the human brain of older adults. [PDF]

J Neuroinflammation
Godoy JB, Vialle RA, Dos Santos L, Raittz RT, Wang Y, Menon V, De Jager PL, Schneider JA, Tasaki S, Bennett DA, Guizelini D, de Paiva Lopes K.   +11 more
europepmc   +1 more source

NKCC1: A key regulator of glioblastoma progression

Molecular Oncology, EarlyView.
Glioblastoma (GBM) progression is driven by disrupted chloride cotransporter homeostasis. NKCC1 is highly expressed in stem‐like, astrocytic, and progenitor cells, correlating with earlier recurrence, while overall survival remains unaffected. NKCC1 serves as a prognostic marker and potential therapeutic target, linking chloride transporter imbalance ...
Anja Thomsen, Diana Freitag, Madlen Haase, Christian Senft, Falko Schwarz, Silke Keiner   +5 more
wiley   +1 more source

Expression Profile of circRNA in Lung Cancer Cells Infected with <i>Staphylococcus aureus</i>. [PDF]

Thorac Res Pract
Ece D, Ozdenizer C, Muftuoglu C, Mert U, Caner A.   +4 more
europepmc   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

Gene Expression Profile-Based Test to Predict Melanoma Sentinel Node Status: The MERLIN_001 Study. [PDF]

JAMA Surg
Hieken TJ, Egger ME, Angeles CV, Hyngstrom JR, Burke EE, Lowe MC, Beasley GM, Bartlett EK, Bresler SC, Harms KL, Zager JS, Lehman JS, Wasif N, Bagaria SP, McMasters KM, Wada DA, Pandalai P, Delman KA, Lee J, Busam KJ, Messina JL, Sondak VK.   +21 more
europepmc   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Expression Profile of Metabotropic Glutamate Receptors in Lung Adenocarcinoma: GRM5 and Validation of Its Targeting Drug Cinchonine. [PDF]

Int J Mol Sci
Xue Y, Liu W, Wang Y, Tao P, Yuan Y, Liu C, Chen S, Song C.   +7 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source